Critical Path Opportunities List Previewed By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Critical Path opportunities list will emphasize development in disease areas with “urgent needs” and “at risk” patient populations, CDER Director Galson says.
You may also be interested in...
FDA To Provide Updates On Agency Involvement In Critical Path Projects
Agency opportunities list highlights 76 “scientific projects” that could modernize the medical product development process.
FDA To Provide Updates On Agency Involvement In Critical Path Projects
Agency opportunities list highlights 76 “scientific projects” that could modernize the medical product development process.
CDER Reorganization Will Create Center-Level Associate Director For Safety
Proposed realignment also will include a new office to serve as a nexus for FDA's Critical Path initiatives.